Novo Nordisk ends collaboration with Heartseed
As part of Novo Nordisk’s restructuring, the company has chosen to discontinue its cell therapy collaboration with Heartseed.
October 6, 2025
In 2021 Heartseed and Novo Nordisk entered into an exclusive worldwide collaboration and license agreement for development, manufacturing and commercialization of Heartseed’s HS-001, an investigational cell therapy using purified cardiomyocytes derived from induced pluripotent stem cells (iPSC).
Novo Nordisk to reduce its workforce by 9,000
Novo Nordisk intends to reduce the global workforce by approximately 9,000 of the 78,400 positions in the company, with around 5,000 reductions expected in Denmark.
Now, Novo Nordisk has called off the deal due to “strategic reviews and shifts” in its business, Heartseed reported on September 30, according to Fierce Biotech.
Published: October 6, 2025
